Xiangjiao Meng

机构：Shandong Tumor Hospital, Shandong First Medical University · ORCID：0000-0001-7380-5510

发表论文 158 篇 · 总被引 4412 次 · h-index 34

代表论文

• A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial (2025 · Nature Medicine · 被引 88)
• Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 60)
• Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial (2025 · BMJ · 被引 41)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
• Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies (2025 · Signal Transduction and Targeted Therapy · 被引 14)
• Deep imaging of LepR+ stromal cells in optically cleared murine bone hemisections (2025 · Bone Research · 被引 8)